{
    "title": "Merck to move COVID-19 treatment into large trials, sees sales recovering this year",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-8580281/Merck-profit-beats-estimates-resilient-Keytruda-demand.html",
    "date": "2020-07-31",
    "keywords": [
        "year",
        "covid19",
        "coronavirus",
        "merck",
        "quarter",
        "erman",
        "treatment",
        "hit",
        "profit",
        "drug",
        "end",
        "vaccine",
        "research",
        "pandemic",
        "company",
        "july",
        "co",
        "friday",
        "drugmaker",
        "ridgeback",
        "gilead",
        "remdesivir",
        "acquisition",
        "bioscience",
        "organization",
        "iavi",
        "dose",
        "globally",
        "disease",
        "barrier",
        "vaccination",
        "example",
        "administration",
        "head",
        "roger",
        "perlmutter",
        "conference",
        "call",
        "revenue",
        "decline",
        "drop",
        "estimate",
        "return",
        "business",
        "healthcare",
        "system",
        "access",
        "balance",
        "officer",
        "robert",
        "secondquarter",
        "blockbuster",
        "cancer",
        "sale",
        "street",
        "forecast",
        "share",
        "range",
        "reporting",
        "bengaluru",
        "michael",
        "maplewood",
        "jersey",
        "editing",
        "bernard",
        "orr",
        "jonathan",
        "oatis",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}